Retinitis pigmentosa (RP) is a group of inherited eye diseases that cause the light-sensing cells in the retina to break down over time, leading to progressive vision loss. It affects roughly 1 in 4,000 people worldwide. The condition typically begins with difficulty seeing in the dark during childhood and gradually narrows the field of vision over decades, sometimes leading to blindness.
How Vision Loss Progresses
The retina contains two types of light-detecting cells: rods and cones. Rods handle low-light and peripheral vision. Cones handle color, detail, and central vision. In RP, a genetic mutation first kills the rod cells. This is why the earliest symptom is almost always night blindness, often noticeable in childhood when a child has unusual difficulty navigating dark rooms or adjusting to dim lighting.
As rods continue to die, peripheral vision shrinks. You may start missing things at the edges of your sight, bumping into doorframes, or losing track of objects that aren’t directly in front of you. Over years, the visual field narrows further into what’s commonly called tunnel vision, where only a small central window of sight remains.
The critical turning point happens after most of the rods are gone. Their death changes the chemistry of the surrounding retinal tissue. Rods normally consume a large amount of oxygen, so when they disappear, oxygen levels in the outer retina spike. That excess oxygen triggers a cascade of oxidative damage in the surviving cone cells, essentially overwhelming their natural defenses with harmful molecules. This is what eventually destroys central vision too. The rate at which rods degenerate varies significantly from person to person and is one of the strongest predictors of long-term outlook, because cones generally don’t begin dying until nearly all rods are gone.
Genetic Causes and Inheritance
More than 60 genes have been linked to RP, which is why the disease varies so much in severity and speed of progression. It follows three main inheritance patterns:
- Autosomal dominant: One copy of a mutated gene from one parent is enough to cause the disease. Over 20 genes are associated with this form. Mutations in the RHO gene are the single most common cause, responsible for 20 to 30 percent of autosomal dominant cases.
- Autosomal recessive: Both parents must carry and pass on a copy of the mutated gene. At least 35 genes are involved. The most frequently implicated is USH2A, accounting for 10 to 15 percent of autosomal recessive cases.
- X-linked: The mutation sits on the X chromosome, so it primarily affects males while females are usually carriers. Mutations in the RPGR and RP2 genes together account for most X-linked cases. This form tends to progress more quickly.
Because of this genetic complexity, two people with RP can have very different experiences. One person may retain functional vision into their 60s or 70s, while another may lose most useful sight by their 30s or 40s.
Syndromic Forms of RP
In some cases, RP is part of a broader genetic syndrome that affects other parts of the body. The most common is Usher syndrome, which accounts for about 18 percent of all RP cases. People with Usher syndrome experience both progressive vision loss and sensorineural hearing loss, and some also develop balance problems.
Bardet-Biedl syndrome is rarer and combines RP with obesity, kidney dysfunction, extra fingers or toes, and sometimes intellectual disability. Other syndromic associations include Refsum disease (a metabolic disorder causing coordination problems and nerve damage), Kearns-Sayre syndrome (a mitochondrial disorder affecting eye muscles and heart rhythm), and Senior-Løken syndrome (which pairs RP with early-onset kidney disease). If RP is diagnosed alongside symptoms outside the eyes, genetic testing can help identify whether a broader syndrome is involved.
How RP Is Diagnosed
An eye exam alone can raise suspicion, but confirming RP requires specialized testing. The hallmark diagnostic tool is the electroretinogram (ERG), which measures the electrical activity of rods and cones across the retina. In RP, the electrical responses from both cell types are diminished, with rod responses typically affected first and more severely.
Optical coherence tomography (OCT) provides a cross-sectional image of the retina and allows doctors to track how much of the photoreceptor layer remains intact. The width of the surviving photoreceptor zone on OCT correlates with how much visual acuity a person still has. Additional tests like visual field mapping and retinal autofluorescence imaging help establish the current extent of vision loss and monitor progression over time. Genetic testing is increasingly used to identify the specific mutation, which matters both for family planning and for determining eligibility for targeted treatments.
Treatments and Management
There is no cure for RP, but several approaches can slow progression or partially restore function depending on the stage and genetic cause.
Gene Therapy
The most significant treatment breakthrough so far is a gene therapy approved by the FDA for people with RP caused by mutations in both copies of the RPE65 gene. This therapy delivers a working copy of the gene directly into retinal cells. RPE65 mutations represent a small fraction of all RP cases, but for those who qualify, the treatment can meaningfully improve vision. Genetic testing is the only way to determine eligibility.
Vitamin A Supplementation
A large clinical trial found that a daily supplement of 15,000 IU of vitamin A in the palmitate form slowed the rate of vision loss in most adults with common forms of RP. Researchers estimated that someone who began supplementation at age 32 could retain useful vision until about age 70, compared to age 63 without it. That’s a meaningful difference, though not a dramatic one.
There are important caveats. Doses above 25,000 IU daily over the long term can cause liver damage. Women who are pregnant or may become pregnant should not take this dose, as high vitamin A intake is linked to birth defects. Beta-carotene supplements are not a reliable substitute because the body converts them to vitamin A at unpredictable rates. The same trial also found that high-dose vitamin E supplements (400 IU daily) appeared to accelerate progression, so people with RP are advised to avoid them. Blood levels of vitamin A should be checked before starting supplementation.
Optogenetics
Optogenetic therapy is a newer approach being tested in clinical trials. It works by genetically modifying surviving retinal cells that don’t normally detect light, giving them the ability to respond to light signals. In 2021, researchers reported partially recovering vision in a person who had been blinded by RP. Multiple clinical trials are currently underway, most using a viral vector to deliver the light-sensing gene into retinal cells. The results are preliminary but represent a fundamentally different strategy from gene replacement, because optogenetics doesn’t depend on fixing the original mutation.
Retinal Prostheses
The Argus II retinal prosthesis was the first implanted device approved by the FDA for advanced RP, receiving clearance in 2013. It used a small camera mounted on glasses to capture images, which were processed and transmitted wirelessly to an electrode array implanted on the retina. The device didn’t restore normal vision but allowed some users to perceive light patterns and shapes. Its manufacturer, Second Sight Medical Products, has since ceased operations, and the device is no longer commercially available. Research into next-generation retinal implants continues at other institutions.
Living With RP
Because RP progresses gradually, many people live for decades with functional vision. Early and mid-stage management often focuses on maximizing remaining sight. High-contrast settings on devices, magnification tools, improved lighting at home, and orientation and mobility training all help maintain independence. As peripheral vision narrows, learning to scan the environment with head movements becomes second nature for many people.
The pace of vision loss varies enormously based on the specific genetic mutation, the inheritance pattern, and individual factors. Knowing your exact genetic diagnosis gives you the most useful information for anticipating what lies ahead and whether any current or upcoming treatments might apply to your case.